CollectionsMerck
IN THE NEWS

Merck

NEWS
March 25, 1993 | by Jim Nicholson, Daily News Staff Writer
Emery "Simmie" Simms, a retired employee of the Merck Co., died Saturday. He was 85 and lived in West Philadelphia. Simms worked for Merck Co., formerly Merck, Sharpe & Dohme, for more than 30 years, primarily as a truck driver. He retired 23 years ago from the firm's facility in West Point, Montgomery County. "He was a very caring and generous man who loved his family and took care of everybody," said Sylvia Knight, a granddaughter. She said that if the weather was bad, her grandfather would telephone her to be sure she got home from work all right.
NEWS
September 28, 2011
Johnson & Johnson and Merck & Co. agreed to end a 22-year-old joint venture that sold consumer pharmaceutical products such as Pepcid and Mylanta brands. Both companies have big operations in the Philadelphia are. J&J, through its McNeil Consumer Healthcare division, will pay Merck $175 million, continue to market those products in the U.S. and Canada, and take full ownership of the factory in Lancaster. The new name for that business will be McNeil Consumer Pharmaceuticals Co. Merck still keeps rights to those products outside the U.S. and Canada.
NEWS
March 18, 2011
The Michigan appeals court says the state cannot sue drug maker Merck to try to recover millions of dollars spent on Vioxx, which was pulled from the market in 2004. The court said Friday that Merck is protected by a unique Michigan law that grants immunity to companies if a drug has been approved by federal regulators. The state attorney general's office is trying to recover money spent on behalf of Medicaid recipients who used Vioxx, an arthritis drug that was pulled from the market because of links to heart attack, stroke and death.
NEWS
August 18, 2010
The Inquirer's article "PRWT to return factory to Merck," published last Wednesday, misstated several facts and inaccurately suggested that PRWT's performance as a manufacturer of active pharmaceutical ingredients for Merck was less than stellar. PRWT, like most small companies in the current United States economy, has found it increasingly difficult to finance current operating and capital expenses and support growth initiatives. The decision to sell the Cherokee plant results directly from the weak economy and "the challenging business environment in the pharmaceutical industry.
BUSINESS
August 1, 2002 | FROM INQUIRER WIRE SERVICES
Merck & Co. Inc., citing market conditions, yesterday withdrew the $1 billion initial public offering of its Medco Health Solutions Inc. business. Merck has been trying to spin off the pharmacy benefit management unit, and the company said it still hoped to do so within a year, "subject to market conditions. " Merck spokesman Chris Loder said withdrawing the regulatory filing for the offering was a formality. The registration statement for Medco, of Franklin Lakes, N.J., was filed with the Securities and Exchange Commission on April 17 and amended May 1, May 21, June 13, July 5 and July 9. "If we did not withdraw the statement, Medco would be required to file public filings, even though there are no public stockholders," Loder said.
BUSINESS
February 24, 2013 | By David Sell, Inquirer Staff Writer
Merck & Co. Inc., will pay $8.5 million to settle allegations by the Commonwealth of Pennsylvania that the drugmaker inappropriately marketed its controversial painkiller Vioxx, which was withdrawn from the market in 2004. State Attorney General Kathleen G. Kane announced that, after attorneys' fees are paid, $6.9 million will go to the PACE program, which helps low-income seniors buy prescription medicine. Vioxx was first approved by the U.S. Food and Drug Administration in 1999 but was pulled from the market in 2004 amid reports that it was causing health problems, including heart attacks and strokes.
BUSINESS
October 9, 2001 | By Joseph A. Slobodzian INQUIRER STAFF WRITER
Officials at Merck & Co. Inc. called them "records retention guidelines" - routine reminders urging employees to manage and reduce the almost unfathomable amount of paperwork generated by the pharmaceutical giant. African American employees, who have filed class-action discrimination lawsuits against Merck in federal courts in Philadelphia and Albany, Ga., saw the July memo as something more sinister: a thinly veiled nudge to bosses to shred records that could hurt Merck in court.
BUSINESS
March 21, 2006 | By Linda Loyd INQUIRER STAFF WRITER
Merck & Co. Inc. announced it would buy rights to promising compounds that treat pain and other neurological disorders - in a deal worth up to $475 million - from Neuromed Pharmaceuticals Ltd., a Conshohocken company developing pain medicines. The companies said yesterday that Merck would pay an initial $25 million for exclusive rights to Neuromed's experimental drugs, including Neuromed's lead compound, NMED-160, a calcium channel blocker to treat chronic pain in mid-stage Phase 2 clinical trials.
NEWS
June 4, 1997 | By Douglas Belkin, INQUIRER CORRESPONDENT
Merck Co. officials and anxious township residents have agreed to try to reach a compromise on the pharmaceutical giant's plans for a massive addition to its facility on Broad Street. Merck has petitioned the township for a zoning change that would allow it to build a three-story, 620,000-square-foot office complex - about half the size of Montgomery Mall - as well as a 2,615-space parking lot. The 46-acre site is zoned for single-family homes on half-acre lots. After more than 100 residents turned out at a Planning Commission meeting Monday night to protest Merck's proposal, the commission tabled the application until a 14-member residents' committee could meet with company representatives.
« Prev | 1 | 2 | 3 | 4 | 5 | Next »
|
|
|
|
|